René Holm, PhD
|
Dr. René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined H. Lundbeck A/S in 2001 and then moved to Janssen in 2016, where he headed drug product development for parenteral and liquid formulations. Dr. Holm has worked within pharmaceutical development and the associated process development, developability in drug discovery, physical chemistry and material science covering both small and large molecules and have been deeply involved in several INDs with advantaged drug delivery. As of 2021 Dr. Holm has been a full professor in Pharmaceutical physical chemistry at the university of Southern Denmark.
Dr. Holm is (co-) author of more than 240 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is an honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark
Mikael Thomsen, PhD
|
Dr. Mikael Thomsen has more than 25 years of experience from the pharma and biotech industry and worked within different major pharmaceutical companies including Novartis Pharma, Switzerland, Novo Nordisk, Denmark as well as at the U.S. Food and Drug Administration. He is co-founder of numerous international biotech companies including Contera Pharma. He is an experienced Clinical Pharmacologist and has had roles as Head of Clinical Pharmacology, VP Development, Chief Development Officer and Chief Scientific Officer, where he managed departments organizing all the activities leading a drug from late Discovery trough clinical development. He has been involved in several product filings as well as interactions with authorities from EMA, FDA and MHLW (Japan).
Mikael Thomsen has two M. Sc. degrees (Pharmacy and Human Biology; from University of Pharmaceutical Sciences, Copenhagen and University of Copenhagen, Medical Faculty) and has a PhD in Pharmacology and Toxicology (University of Copenhagen and FDA site, Arkansas, US) and a degree in Pharmaceutical Medicine (ECPM, Basel, Switzerland). He is a member of several pharmaceutical societies and has authored or co-authored more than 50 publications/abstracts related to drug development as well co-author of several patents.
Seong-Beom Koh, MD, PhD
|
Professor Seong-Beom Koh, MD, PhD, is a neurologist at Korea University | KU, Department of Neurology, in Seoul. He has contributed significantly to the field of movement disorders, with special focus on Parkinson´s disease, and has authored or co-authored more than 150 publications.
January 2022 ~ today: 9th President of The Korean Movement Disorder Society
September 2006 – August 2007: Research Associate of MRC Clinical Sciences Centre, London, United Kingdom
March 2003 ~ today: Director neurology Korea University Guro Hospital, Seoul, South-Korea
March 2001 – today: Professor (Full), Department of Neurology, Korea University, Seoul, South-Korea
Dr. René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined H. Lundbeck A/S in 2001 and then moved to Janssen in 2016, where he headed drug product development for parenteral and liquid formulations. Dr. Holm has worked within pharmaceutical development and the associated process development, developability in drug discovery, physical chemistry and material science covering both small and large molecules and have been deeply involved in several INDs with advantaged drug delivery. As of 2021 Dr. Holm have been a full professor in Pharmaceutical physical chemistry at the university of Southern Denmark.
Dr. Holm is (co-) author of more than 240 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is an honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark.
Dr. Mikael Thomsen has more than 25 years of experience from the pharma and biotech industry and worked within different major pharmaceutical companies including Novartis Pharma, Switzerland, Novo Nordisk, Denmark as well as at the U.S. Food and Drug Administration. He is co-founder of numerous international biotech companies including Contera Pharma. He is an experienced Clinical Pharmacologist and has had roles as Head of Clinical Pharmacology, VP Development, Chief Development Officer and Chief Scientific Officer, where he managed departments organizing all the activities leading a drug from late Discovery trough clinical development. He has been involved in several product filings as well as interactions with authorities from EMA, FDA and MHLW (Japan).
Mikael Thomsen has two M. Sc. degrees (Pharmacy and Human Biology; from University of Pharmaceutical Sciences, Copenhagen and University of Copenhagen, Medical Faculty) and has a PhD in Pharmacology and Toxicology (University of Copenhagen and FDA site, Arkansas, US) and a degree in Pharmaceutical Medicine (ECPM, Basel, Switzerland). He is a member of several pharmaceutical societies and has authored or co-authored more than 50 publications/abstracts related to drug development as well co-author of several patents.
Professor, Korea University, Seoul, South-Korea
Professor Seong-Beom Koh, MD, PhD, is a neurologist at Korea University | KU, Department of Neurology, in Seoul. He has contributed significantly to the field of movement disorders, with special focus on Parkinson´s disease, and has authored or co-authored more than 150 publications.
January 2022 ~ today: 9th President of The Korean Movement Disorder Society
September 2006 – August 2007: Research Associate of MRC Clinical Sciences Centre, London, United Kingdom
March 2003 ~ today: Director neurology Korea University Guro Hospital, Seoul, South-Korea
March 2001 – today: Professor (Full), Department of Neurology, Korea University, Seoul, South-Korea